Thalagen (autologous CD34+ cells transduced with TNS9.3.55) / San Rocco Therap, Memorial Sloan-Kettering Cancer Center - LARVOL DELTA

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Viral vector • Beta-Thalassemia • Genetic Disorders • CD34

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Jul 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Viral vector • Beta-Thalassemia • Genetic Disorders • CD34

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2022 ➔ Jul 2023 | Trial primary completion date: Jul 2022 ➔ Jul 2023

Trial completion date • Trial primary completion date • Beta-Thalassemia • Genetic Disorders • CD34

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov) - P1; N=10; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Jul 2021 ➔ Jul 2022; Trial primary completion date: Jul 2021 ➔ Jul 2022

Clinical • Trial completion date • Trial primary completion date • Beta-Thalassemia • Genetic Disorders • CD34 • MRI

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov) - P1; N=10; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Jul 2020 ➔ Jul 2021; Trial primary completion date: Jul 2020 ➔ Jul 2021

Clinical • Trial completion date • Trial primary completion date • CD34

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene (clinicaltrials.gov) - P1; N=10; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Jul 2019 ➔ Jul 2020; Trial primary completion date: Jul 2019 ➔ Jul 2020

Clinical • Trial completion date • Trial primary completion date